T2 Biosystems

T2 Biosystems Quick Ratio

The Quick Ratio (Acid Test) of T2 Biosystems (TTOO) as of Oct 28, 2026 is 0.30. In the previous year, Quick Ratio (Acid Test) was 0.81 — a change of -62.67% (lower).

Quick Ratio

0.30

YoY

-62.67%

Last updated:

Quick Ratio (Acid Test) of T2 Biosystems is 2023 0.30 . Quick Ratio (Acid Test) of T2 Biosystems was 2022 0.81 . It decreases by -62.67% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

T2 Biosystems Stock analysis

What does T2 Biosystems do? T2 Biosystems, Inc. generates revenue through its T2 Magnetic Resonance platform (T2MR), which detects pathogens and biomarkers in unpurified patient samples like whole blood and urine. The company's primary products are the T2Dx Instrument (T2Dx) and the T2Candida Panel, targeting sepsis, hemostasis, and Lyme disease. Hospitals and clinical laboratories purchase these solutions to diagnose infections rapidly without sample purification, leveraging the platform's ability to detect targets at one colony forming unit per milliliter (CFU/mL). The firm focuses on healthcare providers seeking efficient diagnostic tools for critical conditions. The T2MR platform uses magnetic resonance technology to measure water molecule reactions in magnetic fields, enabling detection of molecular targets such as DNA and proteins. This approach allows for direct analysis of complex samples without preprocessing, appealing to medical facilities needing fast, accurate results. The company's initial development efforts center on sepsis, hemostasis, and Lyme disease, aligning with high-demand diagnostic areas in clinical practice. T2 Biosystems' products are designed for use in healthcare settings where rapid pathogen detection is essential, such as emergency departments and microbiology labs. The T2Dx Instrument and T2Candida Panel serve as key revenue streams, with the latter specifically targeting Candida infections in blood samples. By addressing unmet needs in infectious disease diagnostics, the company caters to a segment of healthcare providers focused on improving patient outcomes through advanced diagnostic capabilities. T2 Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about T2 Biosystems stock

Quick Ratio (Acid Test) of T2 Biosystems is 0.30 in 2023.

Quick Ratio (Acid Test) of T2 Biosystems changed from 0.81 to 0.30, representing a -62.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) T2 Biosystems since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s T2 Biosystems with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — T2 Biosystems

All Key Metrics — T2 Biosystems